Zydus Lifesciences Limited SHARE PRICE [LIVE]

BSE: 532321
To view real time prices Login to your account
Already an existing customer? - Login Now!
BSE Click here to view BSE data
Live Chart
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
Div yield:

Fundamental analysis


0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Underperformed both Sector by -3.4% and Sensex by -18.64%
MARKET CAP (Large Cap Stock)Rs 41,095 Cr
PE (TTM) 21.16
PE Ratio21.16
Price to Book Value2.46
EV to EBIT17.82
EV to EBITDA13.64
EV to Capital Employed2.35
EV to Sales2.70
PEG Ratio0.00
Dividend Yield0.62%
ROCE (Latest)13.17%
ROE (Latest)11.65%
NameSep 22Jun 22
Promoters (Change:0.10) 74.98%74.88%
FIIs (Change:-0.26) 2.6%2.86%
Mutual Funds (Change:0.74) 5.36%4.62%
Insurance Companies (Change:0.00) 7.3%7.3%
Other DIIs (Change:0.17) 0.28%0.11%
Non Institution (Change:-0.76) 9.48%10.24%

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in Zydus Lifesciences Limited

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

Zydus Lifesciences Limited News

Frequently Asked Questions

What is the Share price of CADILA HEALTHCARE LTD. (ZYDUSLIFE)?

CADILA HEALTHCARE LTD. (ZYDUSLIFE) share price as of December 8, 2022, on NSE is Rs 412.05 (NSE) and Rs 411.45 (BSE) on BSE.


Yes, You can buy CADILA HEALTHCARE LTD. (ZYDUSLIFE) shares by opening a Demat account with Angel One.


CADILA HEALTHCARE LTD. (ZYDUSLIFE) share can be brought through the following modes:
  1. Direct investment: You can buy CADILA HEALTHCARE LTD. (ZYDUSLIFE) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to CADILA HEALTHCARE LTD. (ZYDUSLIFE) shares.

In which sector do CADILA HEALTHCARE LTD. (ZYDUSLIFE) belong?


What is the total Asset of Cadila Healthcare?

The total asset of Cadila Healthcare is Rs. 27,642 crores.

What is the main business of Cadila Healthcare?

The main business of Cadila Healthcare, now known as Zydus Lifesciences, is to manufacture generic drugs. Headquartered in Ahmedabad, Cadila develops an extensive range of active pharmaceutical ingredients as well as diagnostics, herbal products, skin care products and animal healthcare products.

Who are the promoters of Cadila Healthcare?

The main promoter of Cadila Healthcare is the Zydus Family Trust.

What are the Subsidiaries that comes under Cadila Healthcare?

Some of the subsidiaries under Cadila Healthcare are Zydus Wellness Limited, Zydus Healthcare Limited, Zydus Wellness Products, Dialforhealth Unity Limited, Dialforhealth Greencross Limited, Zydus Animal Health and Investments Limited, Zydus Pharmaceuticals Limited, Biochem Pharmaceutical Industries Limited, and Liva Nutritions Limited.

About Zydus Lifesciences Limited

Today's live share price for Zydus Lifesciences Limited is NSE: ₹ 412.05, BSE: ₹ 411.45 with a current market capitalization of .

Cadila Healthcare Ltd is a well known research-oriented, technology-driven pharmaceutical company focused on the research areas of biotechnology, formulations and Active Pharmaceutical Ingredients. They are an Indian based pharmaceutical company having their presence around the world. They are having their manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. Cadila Healthcare Ltd, the flagship of Zydus Cadila Group was incorporated in May 1995 and they became a public limited company in July 1996. The company's operation includes pharmaceuticals, which includes human formulations, veterinary formulations and bulkdurgs, diagnostics, herbal products, skin care products and OTC products. In the year 1996, the company made a strategic alliance with Gulin Pharma of China and launched Falcigo in India, which is an anti-malarial segment. In May 2000, the company acquired formulation business of Recon Ltd, which strengthens the company in the southern market. In the year 2001, they acquired German Remedies which was the largest M&A in the Indian Pharmaceutical sector and in the same year, they entered into a joint venture with US based Onconova for collaborative research in the field of Oncogenomics. In April 2002, the company acquired Banyan Chemicals, a Vadodara based company with the US FDA approved plant. In the year 2003, German Remedies, Recon Healthcare, Zoom Properties and Zydus Pathline merged with the company. Also, they acquired Alpharma France, which spearheaded the group operations in France. In the same year, the company emerged as a 'Partner of Choice' for Schering AG to manufacture and market the products in India. In November 2004, the company entered into a strategic alliance with Zambon Group in Italy to open up new avenues in contract manufacturing. In the same year, the company entered into a long term strategic pact with Boehringer Ingelheim India Ltd, a wholly owned subsidiary of Boerhringer Ingelheim (BI) to manufacture and market BI's products in India. In the year 2005, the company entered into a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a business unit of Tyco Healthcare to market the product manufactured by the company under a joint label. In the same year, the company signed a 50:50 joint venture with Mayne Pharma of Australia to manufacture generic injectable, cytotoxic (anti-cancer) medicines as well as active pharmacetical ingredients (API) for global markets. During the year 2005-06, the company signed a 50:50 joint venture with one of India's top biotech companies Bharat Serums and Vaccines Ltd (BSV) and formed Zydus BSV Pharma Pvt Ltd to develop, manufacture and market non-infringing and proprietary Novel Drug Delivery System (NDDS) of an approved anti-cancer product for global markets. During the year 2006-07, the company entered into share purchase agreement to acquire 97.95% stake in Liva Healthcare Ltd, which is carrying on business of manufacturing and marketing of Formulations. They established a green field facility for Solid Oral Dosage Forms in Sikkim mainly for domestic market. They also installed Lyophilisation facility at Moraiya plant with annual capacity of 7.5 million dosages to cater to both Indian and International markets. During the year 2007-08, the company restructured their formulation division namely Alidac and launched two new sub division namely Corza and Fortiza. Also, they forayed into the neutraceutical industry and launched a new division, Zydus Nutriva. The upgradation of the injectibles facility at Moraiya was completed and also, they expanded their manufacturing facility at Ankleshwar. Zydus Healthcare Brasil Ltd, Brazil, a wholly owned subsidiary of the company acquired 100% shareholding of Quimica e Farmaceutica Nikkho Do Brasil Ltda, a Brazilian Pharmaceutical company to expand their branded business in Brazil. Also, Zydus Pharmaceuticals Inc, Japan, a wholly owned subsidiary of the company acquired 100% shareholding in Nippon Universal Pharmaceuticals Co Ltd, Japanese Company, which is carrying out business of manufacturing and marketing of pharmaceutical products in Japan. In February 2008, the company and Karo Bio of Sweden made a three year strategic collaboration in the area of drug discovery and development. The company is in the process of setting up a fine chemical facility at Dabhasa at a cost of about Rs 200 million, which will commence their production in the financial year 2008-09. In May 2008, the company entered into Spain with the acquisition of 100% stake in Laboratories Combix. In June 2008, the company through their wholly owned subsidiary, Zydus Healthcare SA Pty Ltd is acquiring majority state of 70% in Simayla Pharmaceuticals of South Africa. The company decided to demerge the Consumer Products Division of the company and transferred to Carnation Nutra Analogue Foods Ltd, which is a subsidiary of Cadila Healthcare and the merger of Zydus Hospital and Medical Research Pvt Ltd with the company. In August 2008, the company has entered into an agreement with WHO to explore a possible collaboration in the development of a cocktail for the treatment of rabies, through the use of monoclonal antibodies.

Read more

Enjoy Zero Brokerage on Equity Delivery

Join our 1 Cr+ happy customers